Aptevo Therapeutics Inc（APVO）資訊與事件APVOAptevo Therapeutics Inc

Aptevo Therapeutics Reports 93% Clinical Benefit Rate

Aptevo Therapeutics announced a 93% clinical benefit rate with its mipletamig triplet in evaluable frontline acute myeloid leukemia - AML - patients with TP53 mutations, one of the most difficult-to-treat forms of the disease and a patient population that has historically responded poorly to treatment. Of 14 evaluable TP53-mutated patients treated with mipletamig in combination with venetoclax and azacitidine, including two patients from the previously completed dose expansion trial, 13 - 93% - experienced clinical benefit. Eleven patients achieved CR or CRi - 79% -, including nine complete remissions. These results are encouraging because patients with TP53-mutated AML have historically had limited treatment success. The 79% CR/CRi rate observed with the mipletamig triplet compares favorably with a published 41% composite remission rate for venetoclax plus azacitidine in treatment-naive patients with poor-risk cytogenetics and TP53-mutated AML. Currently, the RAINIER study is evaluating mipletamig in combination with venetoclax and azacitidine in frontline AML patients who are unfit to receive standard high-intensity chemotherapy in a dose optimization trial. This phase of the trial is expected to be completed by year-end, and regulatory interaction is planned for 1H27 to determine next steps.

Selling Stockholders Plan to Sell 6.44M Shares of Common Stock

This filing relates to the offer and sale from time to time by the selling stockholders of up to 6.44M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.

Aptevo Therapeutics Signs Warrant Inducement Agreements, Expected to Raise $4.5M

Aptevo Therapeutics announced it has entered into warrant inducement letter agreements with certain holders of its existing common warrants, pursuant to which such holders have agreed to exercise in full for cash their Existing Warrants to purchase up to an aggregate of 254,922 shares of common stock of the company at a reduced exercise price of $4.03 per share. In consideration for such cash exercises, the company will issue new unregistered common stock purchase warrants to purchase up to an aggregate of 1,274,610 shares of common stock at an exercise price of $4.03 per share. The Inducement Warrants will be exercisable on or after the date on which the company obtains the required stockholder approval and will expire five years after their initial exercise date. Separately, pursuant to a securities purchase agreement, the company agreed to sell to certain purchasers in a private placement up to 861,708 unregistered shares of common stock at a purchase price of $4.03 per share, together with common stock purchase warrants to purchase up to 4,308,540 shares of common stock at an exercise price of $4.03 per share. The Pre-Funded Warrants will be exercisable immediately and will expire upon exercise in full, and the Common Warrants will be exercisable on or after the date on which the company obtains the required stockholder approval and will expire five years after their initial exercise date. The aggregate gross proceeds from the transactions described herein are expected to total approximately $4.5M, before deducting placement agent fees and expenses. The transactions are expected to close on or about August 13, subject to satisfaction of customary closing conditions. Roth Capital Partners is acting as the company's exclusive placement agent in connection with these transactions.